Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Med
Päätekijät: Tissino, Erika, Benedetti, Dania, Herman, Sarah E.M., ten Hacken, Elisa, Ahn, Inhye E., Chaffee, Kari G., Rossi, Francesca Maria, Dal Bo, Michele, Bulian, Pietro, Bomben, Riccardo, Bayer, Elisabeth, Härzschel, Andrea, Gutjahr, Julia Christine, Postorino, Massimiliano, Santinelli, Enrico, Ayed, Ayed, Zaja, Francesco, Chiarenza, Annalisa, Pozzato, Gabriele, Chigaev, Alexandre, Sklar, Larry A., Burger, Jan A., Ferrajoli, Alessandra, Shanafelt, Tait D., Wiestner, Adrian, Del Poeta, Giovanni, Hartmann, Tanja Nicole, Gattei, Valter, Zucchetto, Antonella
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Rockefeller University Press 2018
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789417/
https://ncbi.nlm.nih.gov/pubmed/29301866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171288
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia